{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T07:54:33Z","timestamp":1793519673175,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1471,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1038\/s41379-018-0118-3","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T10:09:11Z","timestamp":1535710151000},"page":"147-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":444,"title":["Molecular characterization of cancers with NTRK gene fusions"],"prefix":"10.1016","volume":"32","author":[{"given":"Zoran","family":"Gatalica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Swensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-7265","authenticated-orcid":false,"given":"Semir","family":"Vranic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-018-0118-3_bib1","doi-asserted-by":"crossref","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"10.1038\/s41379-018-0118-3_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","article-title":"Targeting TRK family proteins in cancer","volume":"173","author":"Khotskaya","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1038\/s41379-018-0118-3_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(01)00530-4","article-title":"Trk receptor tyrosine kinases: a bridge between cancer and neural development","volume":"169","author":"Nakagawara","year":"2001","journal-title":"Cancer Lett"},{"key":"10.1038\/s41379-018-0118-3_bib4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0118-3_bib5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1038\/s41379-018-0118-3_bib6","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/pbc.26026","article-title":"Infantile fibrosarcoma with NTRK3\u2013ETV6 fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101","volume":"63","author":"Nagasubramanian","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1038\/s41379-018-0118-3_bib7","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdw042","article-title":"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6\u2013NTRK3 identification in a mammary analogue secretory carcinoma (MASC)","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-018-0118-3_bib8","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/2159-8290.CD-15-0443","article-title":"An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101","volume":"5","author":"Doebele","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1038\/s41379-018-0118-3_bib9","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/labinvest.2017.91","article-title":"New targets bring hope in squamous cell lung cancer: neurotrophic tyrosine kinase gene fusions","volume":"97","author":"Rolfo","year":"2017","journal-title":"Lab Invest"},{"key":"10.1038\/s41379-018-0118-3_bib10","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1517\/13543784.2015.1096344","article-title":"Entrectinib: a potent new TRK, ROS1, and ALK inhibitor","volume":"24","author":"Rolfo","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1038\/s41379-018-0118-3_bib11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.6004\/jnccn.2017.7029","article-title":"Activity of entrectinib in a patient with the first reported NTRK fusion in neuroendocrine cancer","volume":"15","author":"Sigal","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1038\/s41379-018-0118-3_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1158\/1535-7163.MCT-17-0419","article-title":"Antitumor activity of entrectinib, a pan-TRK, ROS1, and ALK inhibitor, in ETV6\u2013NTRK3-positive acute myeloid leukemia","volume":"17","author":"Smith","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/s41379-018-0118-3_bib13","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/01.JTO.0000473485.38553.f0","article-title":"Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer","volume":"10","author":"Farago","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0118-3_bib14","first-page":"1670","article-title":"Targeted therapy: larotrectinib effective against TRK-fusion-positive cancers","volume":"10","author":"Sidaway","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1038\/s41379-018-0118-3_bib15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1038\/s41379-018-0118-3_bib16","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.3390\/cancers10040105","article-title":"Inhibiting TRK proteins in clinical cancer therapy","volume":"10","author":"Lange","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1038\/s41379-018-0118-3_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/1093526617712639","article-title":"Infantile NTRK-associated mesenchymal tumors","volume":"21","author":"Davis","year":"2018","journal-title":"Pediatr Dev Pathol"},{"key":"10.1038\/s41379-018-0118-3_bib18","doi-asserted-by":"crossref","unstructured":"Pavlick D, Schrock AB, Malicki D, Stephens PJ, Kuo DJ, Ahn H, et al. Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatr Blood Cancer. 2017;64.","DOI":"10.1002\/pbc.26433"},{"key":"10.1038\/s41379-018-0118-3_bib19","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.29887","article-title":"NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States","volume":"122","author":"Prasad","year":"2016","journal-title":"Cancer"},{"key":"10.1038\/s41379-018-0118-3_bib20","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1038\/onc.2014.406","article-title":"The landscape and therapeutic relevance of cancer-associated transcript fusions","volume":"34","author":"Yoshihara","year":"2015","journal-title":"Oncogene"},{"key":"10.1038\/s41379-018-0118-3_bib21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/PAS.0000000000000911","article-title":"Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions","volume":"41","author":"Hechtman","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-018-0118-3_bib22","doi-asserted-by":"crossref","first-page":"39028","DOI":"10.18632\/oncotarget.5494","article-title":"NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-018-0118-3_bib23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/modpathol.2017.127","article-title":"Recurrent EML4\u2013NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy","volume":"31","author":"Church","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-018-0118-3_bib24","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/PAS.0000000000001055","article-title":"NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma","volume":"42","author":"Chiang","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-018-0118-3_bib25","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/j.clbc.2017.11.017","article-title":"Rapid response to larotrectinib (LOXO-101) in an adult chemotherapy-naive patients with advanced triple-negative secretory breast cancer expressing ETV6\u2013NTRK3 fusion","volume":"18","author":"Landman","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1038\/s41379-018-0118-3_bib26","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/PAS.0000000000001070","article-title":"Primary and metastatic melanoma with NTRK fusions","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-018-0118-3_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/PAI.0000000000000360","article-title":"Detecting gene rearrangements in patient populations through a 2-step diagnostic test comprised of rapid IHC enrichment followed by sensitive next-generation sequencing","volume":"25","author":"Murphy","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-018-0118-3_bib28","doi-asserted-by":"crossref","unstructured":"Hung YP, Fletcher CDM, Hornick JL. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumor, and histologic mimics. Histopathology. 2018.","DOI":"10.1111\/his.13666"},{"key":"10.1038\/s41379-018-0118-3_bib29","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cam4.1372","article-title":"Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients","volume":"7","author":"Vanderwalde","year":"2018","journal-title":"Cancer Med"},{"key":"10.1038\/s41379-018-0118-3_bib30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2018.02.021","article-title":"Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy","volume":"94","author":"Gatalica","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1038\/s41379-018-0118-3_bib31","doi-asserted-by":"crossref","first-page":"e0130142","DOI":"10.1371\/journal.pone.0130142","article-title":"Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers","volume":"10","author":"Carbognin","year":"2015","journal-title":"PLoS One"},{"key":"10.1038\/s41379-018-0118-3_bib32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1038\/s41379-018-0118-3_bib33","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0118-3_bib34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/EJE-17-0499","article-title":"ETV6\u2013NTRK3 and STRN-ALK kinase fusions are recurrent events in papillary thyroid cancer of adult population","volume":"178","author":"Bastos","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1038\/s41379-018-0118-3_bib35","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/nm.3352","article-title":"Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer","volume":"19","author":"Vaishnavi","year":"2013","journal-title":"Nat Med"},{"key":"10.1038\/s41379-018-0118-3_bib36","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/s41379-018-0118-3_bib37","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J Med Chem"},{"key":"10.1038\/s41379-018-0118-3_bib38","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jtho.2017.01.020","article-title":"A sensitive ALK immunohistochemistry companion diagnostic test identifies patients eligible for treatment with crizotinib","volume":"12","author":"Thorne-Nuzzo","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0118-3_bib39","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2013.54.5921","article-title":"Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project","volume":"32","author":"Blackhall","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0118-3_bib40","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/PAS.0b013e3182960fa7","article-title":"ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas","volume":"37","author":"Sholl","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-018-0118-3_bib41","doi-asserted-by":"crossref","first-page":"e103333","DOI":"10.1371\/journal.pone.0103333","article-title":"Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements","volume":"9","author":"Cha","year":"2014","journal-title":"PLoS One"},{"key":"10.1038\/s41379-018-0118-3_bib42","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/PAS.0000000000001062","article-title":"Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors","volume":"42","author":"Rudzinski","year":"2018","journal-title":"Am J Surg Pathol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0118-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0118-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222011139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222011139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0118-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:45:38Z","timestamp":1760229938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222011139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0893395222011139"],"URL":"https:\/\/doi.org\/10.1038\/s41379-018-0118-3","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular characterization of cancers with NTRK gene fusions","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-018-0118-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}